Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080172 | 1.00 | TDP1 (0.51) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL7641684 | 1.00 | TDP1 (0.51) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL14580010 | 0.98 | TDP1 (0.53) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL1890789 | 0.92 | TDP1 (0.49) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL2224230 | 0.92 | TDP1 (0.54) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL7058682 | 0.91 | TDP1 (0.44) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL6901399 | 0.89 | TDP1 (0.55) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL21073906 | 0.89 | TDP1 (0.55) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL11655565 | 0.87 | TDP1 (0.56) | TDP1KMT2AMEN1L3MBTL1MAPT | |
| SCHEMBL11500452 | 0.84 | TDP1 (0.51) | TDP1KMT2AMEN1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024077796-A1 | PRODUCTION METHOD FOR ETHYL 8-CHLOROOCTANOATE | 扬州市普林斯医药科技有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024077796-A1 | PRODUCTION METHOD FOR ETHYL 8-CHLOROOCTANOATE | 扬州市普林斯医药科技有限公司 | 2024-04-18 | — | — | WO | disclosed |
| CN-115611740-A | Production method of 8-chloro ethyl caprylate | 扬州市普林斯医药科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-115611740-A | Production method of 8-chloro ethyl caprylate | 扬州市普林斯医药科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-113087623-A | Synthesis method of 8-bromoethyl octanoate | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-112409175-A | Synthesis method of 8-chloro ethyl caprylate | 安徽昊帆生物有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3648773-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-05-13 | — | — | EP | disclosed |
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-05-02 | — | — | US | disclosed |
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-05-02 | — | — | US | disclosed |
| US-10195286-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD. (IL) | 2019-02-05 | — | — | US | disclosed |
| US-10195286-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD. (IL) | 2019-02-05 | — | — | US | disclosed |
| US-20190008976-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-01-10 | — | — | US | disclosed |
| WO-2019008574-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008574-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-01-10 | — | — | WO | disclosed |
| US-7038072-B2 | Process for monoalkylation of C-H acidic methylene groups | DEGUSSA AG (DE) | 2006-05-02 | — | — | US | disclosed |
| US-20040054226-A1 | Process for monoalkylation of C-H acidic methylene groups | DEGUSSA AG | 2004-03-18 | — | — | US | disclosed |
| EP-1384706-A1 | Process for the monoalkylation of C-H acid methylene groups | Degussa AG (DE) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195286-B2 | Compounds and methods for trans-membrane delivery of molecules | SLCO2B1, SLCO1B1, ABCB4 | TDP1 2041/4885KMT2A 3655/4885MEN1 1743/4885 |
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, ABCB1, SLCO2B1 | TDP1 2542/4885KMT2A 3594/4885MEN1 1880/4885 |
| US-20190008976-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | SLCO2B1, SLCO1B1, ABCB4 | TDP1 2041/4885KMT2A 3655/4885MEN1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.